{"id":"tacrolimus-tac","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"20-40","effect":"Hypertension"},{"rate":"15-30","effect":"Hyperglycemia"},{"rate":"10-25","effect":"Neurotoxicity (tremor, headache)"},{"rate":"20-40","effect":"Infections"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"5-15","effect":"Gingival hyperplasia"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_fixedAt":"2026-03-30T12:18:54.749980","_dailymed":{"setId":"4eb1b6bd-beec-4dd5-9a48-c93a9fe918b3","title":"TACROLIMUS CAPSULE, EXTENDED RELEASE [AMNEAL PHARMACEUTICALS NY LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12, and this complex inhibits calcineurin phosphatase activity. By blocking calcineurin, it prevents dephosphorylation and nuclear translocation of NFAT, a transcription factor required for IL-2 and other cytokine production. This results in potent immunosuppression, making it effective for preventing organ rejection and treating autoimmune conditions.","oneSentence":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, preventing IL-2 production and T-cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:19.707Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)"},{"name":"Atopic dermatitis"},{"name":"Severe rheumatoid arthritis"},{"name":"Autoimmune uveitis"}]},"_fixedFields":["pubmed(1887)"],"trialDetails":[{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT06365437","phase":"PHASE2","title":"A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation","status":"TERMINATED","sponsor":"ITB-Med LLC","startDate":"2021-06-06","conditions":"Kidney Transplantation","enrollment":33},{"nctId":"NCT02891603","phase":"PHASE1, PHASE2","title":"A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-06-08","conditions":"Graft Vs Host Disease, GVHD","enrollment":40},{"nctId":"NCT06832189","phase":"PHASE1","title":"EVR and EPO for Liver Transplant Tolerance","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-21","conditions":"Liver Transplant","enrollment":20},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT06731504","phase":"EARLY_PHASE1","title":"HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-11-12","conditions":"Hematologic Malignancy","enrollment":10},{"nctId":"NCT05669001","phase":"PHASE2","title":"A Study of TCD601 in de Novo Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2023-12-28","conditions":"Renal Transplantation","enrollment":76},{"nctId":"NCT03605927","phase":"PHASE1","title":"CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-02-15","conditions":"Graft-versus-host-disease, GVHD, GVHD, Acute","enrollment":45},{"nctId":"NCT03674411","phase":"PHASE2","title":"Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2019-01-02","conditions":"Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia","enrollment":22},{"nctId":"NCT06362005","phase":"PHASE4","title":"The Efficacy of Selenium as an Alternative or Complementary Topical Treatment of Oral Lichen Planus","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-05-01","conditions":"Lichen Planus, Oral","enrollment":50},{"nctId":"NCT07290777","phase":"PHASE2","title":"VEL-101 to Prevent Rejection After Kidney Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Veloxis Pharmaceuticals","startDate":"2026-07","conditions":"Transplantation, Kidney","enrollment":120},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT06615050","phase":"PHASE3","title":"A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-04-02","conditions":"Graft-versus-host Disease (GVHD)","enrollment":572},{"nctId":"NCT03841097","phase":"PHASE4","title":"Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roy D. Bloom, MD","startDate":"2019-11-11","conditions":"Kidney Transplant; Complications","enrollment":60},{"nctId":"NCT06315309","phase":"PHASE2","title":"Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-15","conditions":"GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes","enrollment":29},{"nctId":"NCT06265584","phase":"PHASE2","title":"Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-08","conditions":"Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders","enrollment":56},{"nctId":"NCT06235892","phase":"PHASE3","title":"Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Organ Grafts","enrollment":332},{"nctId":"NCT06080490","phase":"","title":"Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2023-09-29","conditions":"Graft Vs Host Disease, Transplant Failure, Stem Cell Transplant Complications","enrollment":125},{"nctId":"NCT06680661","phase":"PHASE2","title":"ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis","status":"RECRUITING","sponsor":"Leland Metheny","startDate":"2025-02-25","conditions":"Acute Myelogenous Leukemia, Acute Lymphatic Leukemia, Chronic Myelogenous Leukemia","enrollment":20},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT02988466","phase":"PHASE2","title":"Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-01-24","conditions":"Hematologic Malignancies","enrollment":78},{"nctId":"NCT03781414","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-10-07","conditions":"Liver Transplant Rejection","enrollment":129},{"nctId":"NCT06960824","phase":"","title":"Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence","status":"NOT_YET_RECRUITING","sponsor":"Chiesi SAS","startDate":"2025-05","conditions":"Chronic Renal Disease","enrollment":165},{"nctId":"NCT04665310","phase":"PHASE4","title":"Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-09-01","conditions":"Kidney Disease, End-Stage, Donor Specific Antibodies, Acute Rejection of Renal Transplant","enrollment":46},{"nctId":"NCT04311632","phase":"PHASE2","title":"A Dose Escalation Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"ITB-Med LLC","startDate":"2021-05-26","conditions":"Kidney Transplantation","enrollment":13},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT06019507","phase":"PHASE2","title":"A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITB-Med LLC","startDate":"2022-06-29","conditions":"Liver Transplantation","enrollment":12},{"nctId":"NCT03737708","phase":"PHASE4","title":"A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2019-02-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":21},{"nctId":"NCT04701528","phase":"PHASE2","title":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-11-15","conditions":"Covid19, Kidney Transplant Infection","enrollment":20},{"nctId":"NCT03410654","phase":"EARLY_PHASE1","title":"Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.","status":"COMPLETED","sponsor":"Yale University","startDate":"2018-10-24","conditions":"Kidney Transplant; Complications","enrollment":28},{"nctId":"NCT04711291","phase":"NA","title":"Efficacy of Envarsus XR and Digital Health Technology in Reducing Tacrolimus Fluctuation and Frequency of Dose Changes","status":"WITHDRAWN","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-06-01","conditions":"Medication Adherence, Renal Transplant","enrollment":""},{"nctId":"NCT05916781","phase":"PHASE4","title":"Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2023-07-01","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis","enrollment":220},{"nctId":"NCT01428973","phase":"PHASE2","title":"Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Liege","startDate":"2011-09","conditions":"Graft-Versus-Host Disease, Hematological Malignancies","enrollment":200},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT06338306","phase":"","title":"Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-01-07","conditions":"Heart Transplant Failure","enrollment":25},{"nctId":"NCT03959241","phase":"PHASE3","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-06-25","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia","enrollment":431},{"nctId":"NCT04207177","phase":"PHASE4","title":"Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2019-10-30","conditions":"Kidney Transplant; Complications, Immune Suppression","enrollment":100},{"nctId":"NCT04936971","phase":"PHASE4","title":"Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response","status":"WITHDRAWN","sponsor":"Edoardo Melilli","startDate":"2021-09","conditions":"Kidney Transplantation, Cytomegalovirus Infections","enrollment":""},{"nctId":"NCT05666336","phase":"PHASE4","title":"Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients","status":"UNKNOWN","sponsor":"Fen Li","startDate":"2022-12-31","conditions":"Systemic Lupus Erythematosus","enrollment":30},{"nctId":"NCT05089604","phase":"PHASE4","title":"Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2023-01-09","conditions":"Liver Transplantation, Immunosuppression, Neurotoxicity","enrollment":124},{"nctId":"NCT06147375","phase":"NA","title":"Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Wei Gao","startDate":"2023-12-01","conditions":"Immune Tolerance, Immunosuppression, Liver Transplant; Complications","enrollment":47},{"nctId":"NCT01951885","phase":"PHASE3","title":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-07-07","conditions":"Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":101},{"nctId":"NCT00905515","phase":"PHASE4","title":"Optima: Optimizing Prograf Therapy in Maintenance Allografts II","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2003-08","conditions":"Kidney Transplantation","enrollment":63},{"nctId":"NCT00821587","phase":"PHASE4","title":"Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation","status":"COMPLETED","sponsor":"University of Florida","startDate":"2004-06","conditions":"Hepatitis C","enrollment":39},{"nctId":"NCT05797038","phase":"","title":"Study on the Application of Hyperspectral Imaging Technique in the Treatment of IMN by TAC","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-04-25","conditions":"Idiopathic Membranous Nephropathy, Tacrolimus, Hyperspectral Imaging","enrollment":40},{"nctId":"NCT01709136","phase":"PHASE2, PHASE3","title":"Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2005-12","conditions":"Hypertension","enrollment":3},{"nctId":"NCT05667922","phase":"","title":"Prognostic Model of TAC in the Treatment of MN","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-06","conditions":"Idiopathic Membranous Nephropathy","enrollment":50},{"nctId":"NCT05667896","phase":"","title":"Prognostic Model of GC/TAC in the Treatment of MN","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2023-06","conditions":"Idiopathic Membranous Nephropathy","enrollment":50},{"nctId":"NCT02206035","phase":"PHASE2","title":"A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant","status":"COMPLETED","sponsor":"William R. Drobyski, MD","startDate":"2014-12","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":45},{"nctId":"NCT02213068","phase":"PHASE4","title":"Belatacept 3 Month Post Transplant Conversion Study","status":"COMPLETED","sponsor":"Lorenzo Gallon","startDate":"2014-07","conditions":"Transplant; Failure, Kidney, EBV","enrollment":28},{"nctId":"NCT05553496","phase":"PHASE2, PHASE3","title":"Assessment of Rituximab Therapeutic Response Versus Conventional Treatment","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-09-25","conditions":"Pharmacological Action","enrollment":40},{"nctId":"NCT05490342","phase":"","title":"Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2022-04-01","conditions":"SARS-CoV-2 Vaccination, Liver Transplantation","enrollment":61},{"nctId":"NCT05471050","phase":"PHASE2","title":"The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-03-02","conditions":"Immune Thrombocytopenia","enrollment":120},{"nctId":"NCT02088931","phase":"PHASE1","title":"Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-03","conditions":"Late Complication From Kidney Transplant","enrollment":3},{"nctId":"NCT04444843","phase":"PHASE4","title":"Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-01-22","conditions":"Kidney Transplant Recipients","enrollment":300},{"nctId":"NCT05221411","phase":"PHASE4","title":"Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-01-19","conditions":"Autoimmune Hepatitis","enrollment":86},{"nctId":"NCT05139667","phase":"PHASE4","title":"Evaluation of Mucoadhesive Tacrolimus Patch on Caspase-3 Inducing Apoptosis in Oral Lichen Planus","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-05-20","conditions":"Oral Lichen Planus","enrollment":30},{"nctId":"NCT02541916","phase":"NA","title":"Liver Immune Tolerance Marker Utilization Study","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2015-04","conditions":"Immunosuppression, Immune Tolerance","enrollment":69},{"nctId":"NCT02217410","phase":"PHASE1, PHASE2","title":"CCFZ533X2201 - PoC Study in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-02-05","conditions":"Kidney Transplantation","enrollment":59},{"nctId":"NCT02588339","phase":"PHASE2","title":"Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-04","conditions":"Graft Versus Host Disease, GVHD","enrollment":42},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01760356","phase":"","title":"Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients","status":"TERMINATED","sponsor":"UDA Centro Nacional Hepato-Bilio-Pancreático","startDate":"2011-05-01","conditions":"End Stage Liver Disease, Rejection, Infection","enrollment":141},{"nctId":"NCT04747080","phase":"PHASE2","title":"The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-03-01","conditions":"ITP, Immune Thrombocytopenia","enrollment":120},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT04114188","phase":"PHASE2","title":"Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2016-12-15","conditions":"Renal Transplant Rejection","enrollment":68},{"nctId":"NCT02083991","phase":"PHASE4","title":"Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Diabetes Mellitus","enrollment":224},{"nctId":"NCT03380936","phase":"EARLY_PHASE1","title":"Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"University of Colorado, Denver","startDate":"2018-01-17","conditions":"Kidney Transplant Rejection","enrollment":4},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT03256864","phase":"PHASE4","title":"Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-01","conditions":"Liver Transplantation","enrollment":10},{"nctId":"NCT01713400","phase":"PHASE2","title":"Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-02-25","conditions":"Graft vs. Host Disease","enrollment":54},{"nctId":"NCT03932539","phase":"","title":"Improving Immunosuppressive Therapy in Heart Transplantation","status":"UNKNOWN","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-05-14","conditions":"Rejection Heart Transplant, Immunosuppression","enrollment":25},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT03864250","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-11-26","conditions":"Tacrolimus, Idiopathic Membranous Nephropathy, Clinical Trial","enrollment":124},{"nctId":"NCT02040584","phase":"PHASE3","title":"A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-20","conditions":"Liver Transplant","enrollment":217},{"nctId":"NCT01551212","phase":"PHASE4","title":"Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05-24","conditions":"Liver Transplantation","enrollment":339},{"nctId":"NCT01878786","phase":"PHASE2, PHASE3","title":"A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys","status":"TERMINATED","sponsor":"Matthew Cooper","startDate":"2013-06","conditions":"Delayed Graft Function","enrollment":25},{"nctId":"NCT03549663","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-04","conditions":"Idiopathic Membranous Nephropathy","enrollment":108},{"nctId":"NCT03751332","phase":"PHASE4","title":"The Vienna Prograf and Endothelial Progenitor Cell Extension Study","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":"Immunosuppression, Renal Failure","enrollment":87},{"nctId":"NCT01580865","phase":"NA","title":"Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2012-05","conditions":"Lupus Nephritis","enrollment":84},{"nctId":"NCT00862979","phase":"PHASE4","title":"A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-02-24","conditions":"Heart Transplantation","enrollment":162},{"nctId":"NCT03596970","phase":"PHASE3","title":"Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Liver Transplantation","enrollment":""},{"nctId":"NCT03365141","phase":"NA","title":"Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo","status":"UNKNOWN","sponsor":"The Catholic University of Korea","startDate":"2017-11-14","conditions":"Vitiligo, Treatment, Intralesional Injection","enrollment":12},{"nctId":"NCT01436305","phase":"PHASE2","title":"Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-09","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":19},{"nctId":"NCT01612299","phase":"NA","title":"Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients","status":"WITHDRAWN","sponsor":"University of Kentucky","startDate":"2012-05","conditions":"Renal Transplant","enrollment":""},{"nctId":"NCT00533442","phase":"PHASE2","title":"Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients","status":"COMPLETED","sponsor":"University of Miami","startDate":"2000-09","conditions":"Type 1 Diabetes","enrollment":170},{"nctId":"NCT01323920","phase":"PHASE2","title":"Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-05","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndrome","enrollment":35},{"nctId":"NCT01598987","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Renal Function, Liver Transplant","enrollment":56},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00141037","phase":"PHASE1, PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"Kidney Diseases, Kidney Transplantation, Kidney Transplant","enrollment":130},{"nctId":"NCT02447055","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2015-12","conditions":"Multiple Myeloma, Myeloma-Multiple","enrollment":""},{"nctId":"NCT01631058","phase":"PHASE4","title":"Renal Transplantation in the Elderly - nEverOld Study","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2012-07","conditions":"Chronic Renal Failure (CRF), Graft Failure, Transplant; Failure, Kidney","enrollment":90},{"nctId":"NCT00707759","phase":"PHASE3","title":"Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection","status":"COMPLETED","sponsor":"Fondo Nacional de Desarrollo Científico y Tecnológico, Chile","startDate":"2008-06","conditions":"Kidney Diseases","enrollment":28},{"nctId":"NCT00166712","phase":"PHASE4","title":"A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2005-04","conditions":"Kidney Transplant Failure and Rejection","enrollment":40},{"nctId":"NCT00803010","phase":"PHASE2","title":"Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2008-09","conditions":"Acute Graft Versus Host Disease","enrollment":74},{"nctId":"NCT01544842","phase":"NA","title":"Tacrolimus Ointment in Oral Lichen Planus","status":"TERMINATED","sponsor":"University of Oulu","startDate":"2004-08","conditions":"Oral Lichen Planus","enrollment":28},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT01324934","phase":"PHASE3","title":"Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids","status":"TERMINATED","sponsor":"Neovii Biotech","startDate":"2006-10","conditions":"Renal Transplant Rejection","enrollment":40},{"nctId":"NCT00525681","phase":"PHASE4","title":"Interaction Between Rimonabant and Cyclosporine and Tacrolimus","status":"COMPLETED","sponsor":"University of Oslo School of Pharmacy","startDate":"2007-09","conditions":"Renal Transplantation","enrollment":18},{"nctId":"NCT01884480","phase":"","title":"Renal Function and Pharmacogenetics in Renal Transplant Recipients Converted From Tac BID to Tac OD","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2013-06","conditions":"Real Function Post Conversion From Prograf to Advagraf, Examin Ethnicity and Pharmacogenetics of the Cohort Requiring Dose Adjustment Post-conversion","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1887,"recentPublications":[{"date":"2026 Mar 28","pmid":"41904367","title":"Urinary MicroRNA Expression and Tacrolimus Pharmacokinetic Variability in Kidney Transplant Recipients: A Cross-sectional Study.","journal":"Clinical drug investigation"},{"date":"2026","pmid":"41884143","title":"Combination of B-cell-guided rituximab and low-dose tacrolimus for primary membranous nephropathy: a retrospective cohort study.","journal":"Frontiers in medicine"},{"date":"2026","pmid":"41858909","title":"Towards Personalized Tacrolimus Dosing Using an Algorithm-Driven Prediction Pipeline for Kidney Transplant.","journal":"Drug design, development and therapy"},{"date":"2026 Mar 17","pmid":"41856260","title":"Multi-center Open-Label Tacrolimus Inhalation Powder (TIP) Trial Evaluating Safety, Tolerability, Efficacy and Pharmacokinetics in Adult Lung Transplant Recipients with Significant Renal Impairment.","journal":"The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation"},{"date":"2026 Feb","pmid":"41841072","title":"Successful Long-Term Use of Isavuconazole in a Tacrolimus-Treated Japanese Kidney Transplant Recipient With Disseminated Cryptococcosis and Probable Invasive Aspergillosis.","journal":"Cureus"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prograf®","FK506","TAC","Protopic","Prograf"],"phase":"marketed","status":"active","brandName":"Tacrolimus (TAC)","genericName":"Tacrolimus (TAC)","companyName":"ITB-Med LLC","companyId":"itb-med-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tacrolimus is a calcineurin inhibitor that suppresses T-cell activation by blocking the phosphatase calcineurin, preventing IL-2 production and T-cell proliferation. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Atopic dermatitis, Severe rheumatoid arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}